Skip to Content
chevron-left chevron-right chevron-up chevron-right chevron-left arrow-back star phone quote checkbox-checked search wrench info shield play connection mobile coin-dollar spoon-knife ticket pushpin location gift fire feed bubbles home heart calendar price-tag credit-card clock envelop facebook instagram twitter youtube pinterest yelp google reddit linkedin envelope bbb pinterest homeadvisor angies

USOR #20423

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)


USOR #20229

Open-Label, Multicenter Trial of Naptumomab Estanfenatox (NAP) in Combination with Docetaxel Following Obinutuzumab Pretreatment in Subjects with Checkpoint Inhibitor Pretreated Advanced or Metastatic Non-Small Cell Lung Cancer (NT-NAP-102-1: PHASE 2a)